The U.S. Supreme Court declined Monday to review a decision absolving Otsuka America Pharmaceutical Inc. of liability in a woman’s suit linking the antipsychotic drug Abilify to her movement disorder.
Mental health continues to be an unmet need, particularly among underserved populations, and the conventional ways of addressing it have not been successful. Otsuka America Pharmaceutical, Inc., a leading pharmaceutical company with a focus on mental health, engaged Real Chemistry to address persistent gaps in treatment with new and innovative solutions.
PRINCETON, N.J. & ROCKVILLE, Md.--(BUSINESS WIRE)--Otsuka America Pharmaceutical, Inc., (Otsuka) today announced that it is Great Place to Work-Certified™. Certification is a significant achievement. Using validated employee feedback gathered with Great Place to Work’s rigorous, data-driven “For All” methodology, Certification confirms at least seven out of 10 employees have a consistently positive experience at Otsuka.
PRINCETON, N.J.--(BUSINESS WIRE)-- Otsuka America Pharmaceutical, Inc. announces today the extension of its patient support program to provide “no-cost” access to its branded portfolio of prescription medicines for patients in the U.S. who have lost a job or health insurance coverage due to the COVID-19 (coronavirus) pandemic
Denmark’s H. Lundbeck A/S and Japan’s Otsuka Pharmaceutical announced that their brexpiprazole failed to meet its primary endpoint in two Phase III clinical trials to treat manic episodes in patients with bipolar I disorder. The drug was approved by the U.S. Food and Drug Administration (FDA) in July 2015 for adjunctive therapy to antidepressants in adults with major depressive disorder and for adults with schizophrenia. It was also approved in Europe and Canada in 2018 and 2017, respectively, to treat schizophrenia. It is marketed under the brand name Rexulti in non-European markets and as Rxulti in Europe.
BASEL, Switzerland--(BUSINESS WIRE)--SK Biopharmaceuticals and Arvelle Therapeutics GmbH today announced that they have entered into an exclusive licensing agreement for Arvelle to develop and commercialize cenobamate in Europe. Cenobamate is a novel, small molecule investigational antiepileptic drug for the potential treatment of partial-onset seizures in adult patients. Under the agreement, SK Biopharmaceuticals will receive an upfront payment of $100 million and is eligible to receive up to $430 million upon achievement of certain regulatory and commercial milestones in addition to royalties on net sales generated in Europe. SK Biopharmaceuticals will have an option to obtain a significant equity stake in Arvelle and will also retain commercial rights for all non-European territories. Cenobamate was discovered and developed by SK Biopharmaceuticals from inception through to the acceptance of a New Drug Application (NDA) by the U.S. Food and Drug Administration (FDA).
Lundbeck and Otuska’s brexpiprazole-sertraline cocktail has hit the mark in a post-traumatic stress disorder (PTSD) phase 2. The data give Lundbeck a boost at a time when its recently installed CEO is hunting for ways to improve on lackluster growth forecasts.
Otsuka Pharma's Rxulti(brexpiprazole) Receives Approval in Europe
Daliresp (Roflumilast) : AstraZeneca vs. Alkem
WASHINGTON, Nov. 16, 2018 /PRNewswire/ -- Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka), a global leader in the development of digital and traditional treatments for mental illness, together with honorary co-host U.S. Representative Bonnie Watson Coleman (NJ-12) hosted a roundtable discussion of the expanding role of technology in the future of healthcare and its potential to break down barriers to care and support patient outcomes.